Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

ACCELERATE DIAGNOSTICS, INC.

(AXDX)
  Report
Delayed Nasdaq  -  04:00:00 2023-02-03 pm EST
0.6891 USD   -4.36%
01/13Accelerate Diagnostics, Inc : Other Events (form 8-K)
AQ
01/11Accelerate Diagnostics, Inc : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)
AQ
2022Accelerate Diagnostics Files Application With US FDA to Update PhenoTest BC Kit
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Valuation
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Capitalization1 92343236468,368,3-
Enterprise Value (EV)1 94551040868,368,368,3
P/E ratio -10,9x-5,41x-4,14x-0,91x-1,29x-2,03x
Yield ------
Capitalization / Revenue 99,3x38,7x30,9x5,40x3,99x3,25x
EV / Revenue 99,3x38,7x30,9x5,40x3,99x3,25x
EV / EBITDA -13 149 836x-7 121 315x-8 557 434x---
Enterprise Value (EV) / FCF -14 180 638x-8 352 368x-7 587 701x---
FCF Yield 0,00%0,00%0,00%---
Price to Book -125x-6,95x-10,1x---
Nbr of stocks (in thousands) 54 64557 03069 66499 09999 099-
Reference price (USD) 16,97,585,220,690,690,69
Announcement Date 02/27/202002/23/202103/08/2022---
1 USD in Million
Previous periodNext period
Estimates
Income Statement Evolution (Annual data)
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Net sales1 9,3011,211,812,717,121,0
EBITDA -70,2-60,7-42,5---
Operating profit (EBIT)1 -72,8-63,7-71,6-60,9-44,1-42,3
Operating Margin -783%-571%-607%-481%-258%-201%
Pre-Tax Profit (EBT)1 -84,4-78,2-77,7-60,3-44,1-42,3
Net income1 -84,3-78,2-77,7-60,3-44,1-42,3
Net margin -907%-700%-659%-477%-258%-201%
EPS2 -1,55-1,40-1,26-0,76-0,54-0,34
Free Cash Flow -65,1-51,8-47,9---
FCF margin -700%-464%-407%---
FCF Conversion 92,7%85,3%113%---
Dividend per Share ------
Announcement Date 02/27/202002/23/202103/08/2022---
1 USD in Million
2 USD
Previous periodNext period
Estimates
Income Statement Evolution (Quarterly data)
Fiscal Period: December 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2
Net sales1 2,963,862,962,853,704,15
EBITDA ------
Operating profit (EBIT)1 -15,9-18,0-14,8-12,2-11,2-11,1
Operating Margin -537%-466%-499%-428%-303%-267%
Pre-Tax Profit (EBT)1 -14,2-17,8-15,7-12,6-11,2-11,1
Net income1 -14,2-17,8-15,7-12,6-11,2-11,1
Net margin -480%-461%-531%-442%-303%-267%
EPS2 -0,21-0,23-0,18-0,15-0,13-0,13
Dividend per Share ------
Announcement Date 05/16/202208/15/202211/14/2022---
1 USD in Million
2 USD
Previous periodNext period
Estimates
Balance Sheet Analysis
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Net Debt 21,678,244,4---
Net Cash position ------
Leverage (Debt / EBITDA) -0,31x-1,29x-1,05x---
Free Cash Flow -65,1-51,8-47,9---
ROE (Net Profit / Equities) ------
Shareholders' equity1 ------
ROA (Net Profit / Asset) -52,7%-68,6%-88,1%---
Assets1 16011488,2---
Book Value Per Share -0,13-1,09-0,52---
Cash Flow per Share ------
Capex 0,331,360,60---
Capex / Sales 3,55%12,2%5,12%---
Announcement Date 02/27/202002/23/202103/08/2022---
1 USD in Million
Previous periodNext period
Estimates
Key data
Capitalization (USD) 68 289 451
Net sales (USD) 11 782 000
Number of employees 220
Sales / Employee (USD) 53 555
Free-Float 73,2%
Free-Float capitalization (USD) 50 020 440
Avg. Exchange 20 sessions (USD) 150 336
Average Daily Capital Traded 0,22%
EPS & Dividend